<DOC>
	<DOC>NCT02941796</DOC>
	<brief_summary>To investigate the pharmacokinetic properties and safety after administration of HCP1105 and co-administration of HGP0918, HGP0816 in healthy male volunteers</brief_summary>
	<brief_title>Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers</brief_title>
	<detailed_description>The purpose of this study is to investigate the pharmacokinetic properties and safety after administration of HCP1105 and co-administration of HGP0918, HGP0816 in healthy male volunteers</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing Healthy male volunteers, aged 19 to 55 years. The result of Body Mass Index(BMI) is not less than 18.5 kg/m2 , no more than 27.0 kg/m2 â€¢Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system Someone has a declined liver function and Liver enzyme (AST, ALT or total bilirubin) level exceeds more than one and a half times normal upper range Somenone has a declined kidney function and his eGFR &lt; 60mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>